Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Ever since their rise in popularity as weight loss drugs, there’s been a slew of reports on the potential adverse health ...

Novo Nordisk has reported net Q3 profits of $3.94bn (DKr27.3bn) fuelled by better-than-expected sales for its blockbuster ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

Both Ozempic and Wegovy are forms of semaglutide, a GLP-1 agonist drug manufactured by Novo Nordisk. When reached for comment ...

A newly published study in the New England Journal of Medicine highlighted this week that Novo Nordisk’s (NVO) GLP-1 agonist ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...

Danish pharma giant Novo Nordisk has said it is aware of at least 10 deaths and 100 hospitalisations linked to compounded versions of semaglutide -- the active ingredient in popular diabetes and ...

Westend61/Getty Images The use of GLP-1 medications such as semaglutide — more widely known under the brand names of Ozempic ...

Wegovy may significantly reduce hospital admissions for any cause and overall length of stay, according to a new analysis of data from Novo Nordisk's phase 3 SELECT trial.

There are two ways to be eligible for a Wegovy prescription: Have a BMI of 30 or higher Have a BMI of 27 or higher and a ...